Abstracts tagged "osteoporosis and treatment"

Abstract Number: 1039 • 2018 ACR/ARHP Annual Meeting
Tenofovir Induces Osteopenia and Dipyridamole, an Inhibitor of the Ent-1 Nucleoside Transporter, Reverses the Osteopenic Effect of Tenofovir In Vivo
Francisco Miguel Conesa-Buendia¹, Patricia Llamas², Tuere Wilder³, Raquel Largo⁴, Gabriel Herrero-Beaumont⁴, Bruce N. Cronstein⁵ and Aranzazu Mediero⁶, ¹Bone and Joint Research Unit, IIS-Fundacion Jimenez Diaz- UAM, Madrid, Spain, ²Bone and Joint Research Unit, IIS-Fundacion Jimenez Díaz-UAM, Madrid, Spain, ³Department of Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ⁴Bone and Joint Research Unit, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, ⁵Rheumatology, New York University School of Medicine, Division of Rheumatology, New York, NY, ⁶Joint and Bone Research Unit, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain
Background/Purpose: Osteopenia and fragility fractures have been associated with HIV infection. Tenofovir, one of the most commonly used antivirals in HIV, also leads to increases…
Abstract Number: 2808 • 2018 ACR/ARHP Annual Meeting
T-Score As an Indicator of Fracture Risk on Therapy: Evidence from Romosozumab Vs Alendronate Treatment in the Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk Trial
Felicia Cosman¹, E. Michael Lewiecki², Peter R Ebeling³, Eric Hesse⁴, Nicola Napoli⁵, Daria B Crittenden⁶, Maria Rojeski⁶, Wenjing Yang⁶, Cesar Libanati⁷ and Serge Ferrari⁸, ¹Columbia University, New York, NY, ²New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ³Monash University, Melbourne, Australia, ⁴University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁵Campus Bio-Medico University of Rome, Rome, Italy, ⁶Amgen Inc., Thousand Oaks, CA, ⁷UCB Pharma, Brussels, Belgium, ⁸Geneva University Hospital, Geneva, Switzerland
Background/Purpose: BMD is a strong predictor of fracture risk in untreated patients. Recent evidence suggests that BMD achieved during treatment also reflects fracture risk; thus,…
Abstract Number: 321 • 2016 ACR/ARHP Annual Meeting
Results of a Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Romosozumab in Men with Osteoporosis
EM Lewiecki¹, S Horlait², T Blicharski³, S Goemaere⁴, K Lippuner⁵, P Meisner⁶, PD Miller⁷, A Miyauchi⁸, J Maddox⁹, NS Daizadeh⁹ and A Grauer⁹, ¹New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ²Amgen Ltd., Uxbridge, United Kingdom, ³Medical University of Lublin, Lublin, Poland, ⁴Ghent University Hospital, Gent, Belgium, ⁵Bern University Hospital, Bern, Switzerland, ⁶UCB Pharma, Brussels, Belgium, ⁷Colorado Center for Bone Research, Lakewood, CO, ⁸Miyauchi Medical Center, Osaka, Japan, ⁹Amgen Inc., Thousand Oaks, CA
Background/Purpose: Treatment with romosozumab (Romo) has been shown to rapidly increase BMD in postmenopausal women with low BMD through a dual effect on bone, increasing…
Abstract Number: 323 • 2016 ACR/ARHP Annual Meeting
Effect of 10 Years of Denosumab Treatment on Bone Histology and Histomorphometry in the Freedom Extension Study
David W Dempster^1,2, NS Daizadeh³, A Fahrleitner-Pammer⁴, Jens-Erik Beck Jensen⁵, DL Kendler⁶, Ivo Valter⁷, Rachel B Wagman³, Susan Yue³ and Jacques P Brown⁸, ¹Columbia University, New York, NY, ²Helen Hayes Hospital, West Haverstraw, NY, ³Amgen Inc., Thousand Oaks, CA, ⁴Medical University, Graz, Austria, ⁵Hvidovre University Hospital, Hvidovre, Denmark, ⁶University of British Columbia, Vancouver, BC, Canada, ⁷Center for Clinical and Basic Research, Tallinn, Estonia, ⁸Centre Hospitalier de l'Université Laval (CHUL), Quebec City, QC, Canada
Background/Purpose: Denosumab (DMAb) has been associated with low incidence of spine and non-spine, including hip, fractures through 10 years of treatment (Bone ASBMR 2015). Questions…
Abstract Number: 336 • 2016 ACR/ARHP Annual Meeting
The Risk of Subsequent Osteoporotic Fractures Is Decreased in Patients Experiencing Fracture While on Denosumab
DL Kendler¹, A Chines², ML Brandi³, S Papapoulos⁴, EM Lewiecki⁵, J-Y Reginster⁶, C Roux⁷, M Munoz Torres⁸, A Wang² and HG Bone⁹, ¹University of British Columbia, Vancouver, BC, Canada, ²Amgen Inc., Thousand Oaks, CA, ³University of Florence, Florence, Italy, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ⁶University of Liège, Liège, Belgium, ⁷Paris Descartes University, Paris, France, ⁸Hospital Universitario San Cecilio, Granada, Spain, ⁹Michigan Bone and Mineral Clinic, Detroit, MI
Background/Purpose: Osteoporosis is a common, progressive condition leading to increased bone fragility and susceptibility to fracture. Although osteoporosis therapy decreases fracture risk, fractures while on…
Abstract Number: 337 • 2016 ACR/ARHP Annual Meeting
Denosumab Treatment for 10 Years in Postmenopausal Women with Osteoporosis Was Associated with Substantially Lower Fracture Incidence Relative to Their Baseline FRAX-Predicted Probability
E Siris¹, N Pannacciulli², PD Miller³, EM Lewiecki⁴, R Chapurlat⁵, E Jódar-Gimeno⁶, NS Daizadeh², RB Wagman² and JA Kanis⁷, ¹Columbia University Medical Center, New York, NY, ²Amgen Inc., Thousand Oaks, CA, ³Colorado Center for Bone Research, Lakewood, CO, ⁴New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ⁵Hôpital Edouard Herriot, Lyon, France, ⁶Hospital Universitario Quirónsalud Madrid, Madrid, Spain, ⁷University of Sheffield, Sheffield, United Kingdom
Background/Purpose: Denosumab is approved for treating postmenopausal women with osteoporosis at high risk for fracture. The placebo-controlled FREEDOM trial and its active-treatment Extension investigated the…
Abstract Number: 1023 • 2016 ACR/ARHP Annual Meeting
Fracture Risk Reduction with Romosozumab: Results of a Phase 3 Study in Postmenopausal Women with Osteoporosis
F Cosman¹, DB Crittenden², JD Adachi³, N Binkley⁴, E Czerwinski⁵, S Ferrari⁶, LC Hofbauer⁷, E Lau⁸, EM Lewiecki⁹, A Miyauchi¹⁰, CAF Zerbini¹¹, CE Milmont², L Chen², J Maddox², PD Meisner¹², C Libanati¹² and A Grauer², ¹Helen Hayes Hospital, West Haverstraw, and Columbia University, New York, NY, ²Amgen Inc., Thousand Oaks, CA, ³McMaster University, Hamilton, ON, Canada, ⁴University of Wisconsin–Madison Osteoporosis Clinical Center and Research Program, Madison, WI, ⁵Krakow Medical Center, Krakow, Poland, ⁶Geneva University Hospital, Geneva, Switzerland, ⁷Division of Endocrinology, Diabetes, and Bone Diseases, TU Dresden Medical Center, Dresden, Germany, ⁸Center for Clinical and Basic Research, Hong Kong, China, ⁹New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ¹⁰Miyauchi Medical Center, Osaka, Japan, ¹¹Centro Paulista de Investigação Clinica, São Paulo, Brazil, ¹²UCB Pharma, Brussels, Belgium
Background/Purpose: Romosozumab (Romo) is an investigational bone-forming monoclonal antibody that binds sclerostin and has a dual effect, increasing bone formation and decreasing bone resorption. Here,…
Abstract Number: 1024 • 2016 ACR/ARHP Annual Meeting
Superior Gains in Bone Mineral Density and Estimated Strength at the Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of a Phase 3, Open-Label Clinical Trial
B Langdahl¹, C Libanati², DB Crittenden³, MA Bolognese⁴, JP Brown⁵, NS Daizadeh³, K Engelke⁶, HK Genant⁷, S Goemaere⁸, Lars Hyldstrup⁹, E Jodar-Gimeno¹⁰, TM Keaveny¹¹, D Kendler¹², P Lakatos¹³, J Maddox³, J Malouf¹⁴, FE Massari¹⁵, JF Molina¹⁶, MR Ulla¹⁷ and A Grauer³, ¹Aarhus University Hospital, Aarhus, Denmark, ²UCB Pharma, Brussels, Belgium, ³Amgen Inc., Thousand Oaks, CA, ⁴Bethesda Health Research Center, Bethesda, MD, ⁵Laval University and CHU de Québec (CHUL) Research Centre, Quebec City, QC, Canada, ⁶BioClinica Inc., Hamburg, Germany, ⁷Department of Radiology, University of California San Francisco, San Francisco, CA, ⁸Ghent University Hospital, Gent, Belgium, ⁹Hvidovre University Hospital, Hvidovre, Denmark, ¹⁰Servicio de Endocrinología, Hospital Universitario Quirón, Madrid, Spain, ¹¹University of California at Berkeley, Berkeley, CA, ¹²University of British Columbia, Vancouver, BC, Canada, ¹³Department of Medicine, Semmelweis University, Budapest, Hungary, ¹⁴Universitat Autònoma de Barcelona, Barcelona, Spain, ¹⁵Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina, ¹⁶Reumalab Centro Integral de Reumatologia, Medellin, Colombia, ¹⁷Instituto Latinoamericano de Investigaciones Médicas, Córdoba, Argentina
Background/Purpose: STRUCTURE was a phase 3, open-label study evaluating the effect of romosozumab or teriparatide for 12 months in women with postmenopausal osteoporosis transitioning from…
Abstract Number: 1028 • 2016 ACR/ARHP Annual Meeting
Discontinuation of Denosumab and Associated Vertebral Fracture Incidence: Analysis from a Phase 3 Placebo-Controlled Study of Denosumab and Its Open-Label Extension
Jacques P Brown¹, S Ferrari², N Gilchrist³, Jens-Erik Beck Jensen⁴, N Pannacciulli⁵, Chris Recknor⁶, Christian Roux⁷, Shawna Smith⁵, Ove Törring⁸, Ivo Valter⁹, Rachel B Wagman⁵, A Wang⁵ and SR Cummings¹⁰, ¹Centre Hospitalier de l'Université Laval (CHUL), Quebec City, QC, Canada, ²Geneva University Hospital, Geneva, Switzerland, ³The Princess Margaret Hospital, Christchurch, New Zealand, ⁴Hvidovre University Hospital, Hvidovre, Denmark, ⁵Amgen Inc., Thousand Oaks, CA, ⁶United Osteoporosis Centers, Gainesville, GA, ⁷Paris Descartes University, Paris, France, ⁸Karolinska Institutet Sodersjukhuset, Stockholm, Sweden, ⁹Center for Clinical and Basic Research, Tallinn, Estonia, ¹⁰SFCC, CPMC Research Institute & UCSF, San Francisco, CA
Background/Purpose: Denosumab (DMAb) treatment has been shown to decrease fracture (Fx) risk. Unlike bisphosphonates, DMAb is a monoclonal antibody against RANKL. Discontinuation is characterized by…
Abstract Number: 125 • 2015 ACR/ARHP Annual Meeting
Implementation of a Bone Health Team Markedly Improves Osteoporosis Screening, Diagnosis and Treatment Initiation Rates Compared to Standard Primary Care Practice
Karla L. Miller^1,2, Marissa P. Grotzke¹, Phillip Lawrence³, Yanina Rosenblum⁴, Richard Nelson^5,6, Joanne Lafleur^7,8 and Grant W. Cannon¹, ¹Internal Medicine, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, ²Internal Medicine-Division of Rheumatology, University of Utah School of Medicine, SLC, UT, ³Pharmacology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁴Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, ⁵Epidemiology, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, ⁶Division of Epidemiology, University of Utah School of Medicine, Salt Lake City, UT, ⁷Pharmacology, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, ⁸University of Utah College of Pharmacy, Salt Lake City, UT
Background/Purpose: Despite the availability of effective therapies for fracture prevention, osteoporosis screening and treatment rates in practice are low. Fracture liaison services are effective at…
Abstract Number: 2255 • 2014 ACR/ARHP Annual Meeting
Vertebral Cortical Bone Mass and Structure Significantly Improved with Romosozumab Compared with Teriparatide: HR-QCT Analyses of Postmenopausal Women with Low BMD from a Phase 2 Study
T Damm¹, C Libanati², J Peña¹, G Campbell¹, R Barkmann¹, DA Hanley³, S Goemaere⁴, MA Bolognese⁵, C Recknor⁶, C Mautalen⁷, YC Yang² and CC Glüer¹, ¹Christian-Albrechts-Universität zu Kiel, Kiel, Germany, ²Amgen Inc., Thousand Oaks, CA, ³University of Calgary, Calgary, AB, Canada, ⁴Ghent University Hospital, Ghent, Belgium, ⁵Bethesda Health Research Center, Bethesda, MD, ⁶United Osteoporosis Centers, Gainesville, GA, ⁷Centro de Osteopatias Medicas, Buenos Aires, Argentina
Background/Purpose : Understanding the effect of therapies in the vertebral compartments is relevant to bone biology and clinical practice. We developed an improved technique using…
Abstract Number: 234 • 2014 ACR/ARHP Annual Meeting
The Decrease in Prescription of Anti-Osteoporotic Drugs Has No Impact on Hip Fracture Incidence
Karine Briot¹, Milka Maravic² and Christian Roux³, ¹Cochin Hospital, Paris Descartes University, Paris, France, ²Hopital Leopold Bellan, Paris, France, ³Paris Descartes University, Cochin Hospital, Paris, France
Background/Purpose Controversies exist about the change in hip fracture incidence among countries. In France, we previously showed that the incidence of hip fractures decreased in…
Abstract Number: 49 • 2014 ACR/ARHP Annual Meeting
Long-Term Oral Bisphosphonate Use for Osteoporosis Among Older Women – US and Canadian Perspective
Nicole C. Wright¹, Wilson Smith², Amy H. Warriner³, Jeff Foster⁴, Ruth McConnell⁵, Huifeng Yun⁶, Mary H Melton⁷, Jeffrey R. Curtis⁴ and Kenneth G. Saag⁸, ¹Epidemiology, The University of Alabama at Birmingham, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Endocrinology, Diabetes, and Metabolism, The University of Alabama at Birmingham, Birmingham, AL, ⁴The University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ⁷Medicine, The University of Alabama at Birmingham, Birmingham, AL, ⁸Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Bisphosphonates (BPs) have been widely used for the treatment and prevention of osteoporosis for two decades. Although new parenteral preparations have been introduced, oral…
Abstract Number: 48 • 2014 ACR/ARHP Annual Meeting
Osteoporotic Women at High Risk for Fractures Despite Two Years of Oral Bisphosphonate Therapy: Analysis Using the Canadian Multicentre Osteoporosis Study
Jonathan D. Adachi¹, David Goltzman², Ankita Modi³, Jackson Tang⁴, Chun-Po S. Fan⁴ and Jessica Weaver³, ¹Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ²McGill University, Montreal, QC, Canada, ³Global Health Outcomes, Merck & Co., Inc., Whitehouse Station, NJ, ⁴Asclepius Analytics, New York, NY
Background/Purpose Individuals with osteoporosis (OP) have an increased susceptibility to fractures. Prevention and treatment of postmenopausal OP is critical to decreasing the risk of non-traumatic…
Abstract Number: 1219 • 2013 ACR/ARHP Annual Meeting
Phase 3 Fracture Trial Of Odanacatib For Osteoporosis – Baseline Characteristics and Study Design
Socrates Papapoulos¹, Henry G. Bone², David W. Dempster³, John Eisman⁴, Susan Greenspan⁵, Michael McClung⁶, Toshitaka Nakamura⁷, Joseph Shih⁸, Albert Leung⁹, Arthur Santora¹⁰, N. Verbruggen¹¹ and Antonio Lombardi¹², ¹Leiden University Medical Center, Leiden, Netherlands, ²Michigan Bone and Mineral Clinic, Detroit, MI, ³Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY, ⁴The Garvan Institute of Medical Research, Sydney, Australia, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶Oregon Osteoporosis Center, Portland, OR, ⁷University of Occupational & Environmental Health, Fukuoaka, Japan, ⁸Robert Wood Johnson Medical School, Piscataway, NJ, ⁹Clinical Research, Merck Sharp and Dohme Corp., Rahway, NJ, ¹⁰Merck Sharp & Dohme Corp., Whitehouse Station, NJ, ¹¹MSD Belgium, Brussels, Belgium, ¹²Merck Sharp and Dohme Corp., Rahway, NJ
Background/Purpose: Odanacatib is a selective and reversible inhibitor of cathepsin K; a collagenase secreted by osteoclasts, and is currently being evaluated for the treatment of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].